Cargando…
Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report
BACKGROUND: Everolimus, an inhibitor of the mammalian target of rapamycin, shows promising antitumor activity when combined with trastuzumab and chemotherapy for human epidermal growth factor receptor-2 (HER2)-positive breast cancer or when combined with endocrine agents for hormone receptor (HR)-po...
Autores principales: | Sun, Bing, Ding, Lijuan, Wu, Shikai, Meng, Xiangying, Song, Santai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936809/ https://www.ncbi.nlm.nih.gov/pubmed/27445490 http://dx.doi.org/10.2147/OTT.S104398 |
Ejemplares similares
-
Sunitinib as salvage treatment including potent anti-tumor activity in carcinomatous ulcers for patients with multidrug-resistant metastatic breast cancer
por: Sun, Bing, et al.
Publicado: (2016) -
A nomogram for predicting survival in patients with breast cancer brain metastasis
por: Huang, Zhou, et al.
Publicado: (2018) -
Cystic brain metastasis is associated with poor prognosis in patients with advanced breast cancer
por: Sun, Bing, et al.
Publicado: (2016) -
Receptor conversion in metastatic breast cancer: a prognosticator of survival
por: Meng, Xiangying, et al.
Publicado: (2016) -
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
por: Schmid, Peter, et al.
Publicado: (2019)